Ticker | Value | Shares | Price | Security | Type | Insider | Title | Return | Flags | Date |
|---|---|---|---|---|---|---|---|---|---|---|
| No transactions found | ||||||||||
Matthew W. Kalnik currently holds 71,050 shares of NABI BIOPHARMACEUTICALS (NABI), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Matthew W. Kalnik has been a net seller of NABI stock. They have purchased $0 and sold $223.9K worth of shares.
Matthew W. Kalnik's most recent insider trade was on Apr 1, 2011, when they sold 30,000 shares at $0.00 per share.
Matthew W. Kalnik serves as Executive at NABI BIOPHARMACEUTICALS (NABI). They have executed 20 insider transactions totaling $223.9K over their tenure at the company.
Matthew W. Kalnik holds the position of Executive at NABI BIOPHARMACEUTICALS, where they are responsible for executive-level decision-making and strategic oversight. They have been associated with the company for 17 years and currently hold a stake valued at $0.
Matthew W. Kalnik has shown a selling trading pattern, with $0 in total purchases and $223.9K in total sales across all transactions. Their most recent activity indicates a tendency to reduce their position.
The largest transaction by Matthew W. Kalnik was on Mar 17, 2010, when they sold $58.5K worth of NABI shares. This transaction involved 9,873 shares at $5.93 per share.
Matthew W. Kalnik currently owns 71,050 shares of NABI BIOPHARMACEUTICALS (NABI), with an estimated value of $0. This stake represents their equity holdings accumulated through purchases, awards, and option exercises.
All of Matthew W. Kalnik's SEC Form 4 insider trading filings are tracked on this page. Each transaction links directly to the official SEC EDGAR filing. Matthew W. Kalnik has 20 Form 4 filings on record as an insider at NABI BIOPHARMACEUTICALS.
Set alerts for Matthew W. Kalnik and 40,000+ other insiders.